Clinical trial
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
NCT00087867 · Scios, Inc., Industry · Completed
Key facts
| NCT number | NCT00087867 |
|---|---|
| Title | Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma |
| Official title | An Open-label Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed, Refractory Patients With Multiple Myeloma |
| Lead sponsor | Scios, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | SCIO-469, SCIO-469 and bortezomib |
| Enrollment | 62 |
| Start date | Jun 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Jul 19, 2004 |
| Last update posted | Oct 18, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: